DIA Biosimilars 2013

Ethics/Regulatory

Report: EMA’s system of comparing drugs is flawed

Friday, September 9, 2011 11:52 AM

The European system of comparing drugs against placebo and not against a comparator is flawed, according to researchers at the London School of Economics, reported InPharm.

More... »

Cenduit: Now with Patient Reminders

New Zealand to streamline ethics committee review system

Friday, September 9, 2011 10:17 AM

The New Zealand government will work over the next 10 months to streamline and simplify processes for ethics committee reviews of clinical trials, according to PharmaTimes.

More... »

CRF Health – eCOA Forum

FDA’s new guidance on monitoring clinical trials strongly encourages taking a risk-based approach

Monday, September 5, 2011 08:02 AM

Arisk-based approach to monitoring clinical trials: It’s the way to go now.

More... »

FDA approves Lupin’s UltramR ER

Wednesday, August 31, 2011 01:04 PM

Lupin Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Extended-Release Tablets, 100, 200 and 300 mg strengths. Lupin will begin shipping its Tramadol ERshortly.

More... »

NIH finalizes changes in conflict of interest rules

Wednesday, August 24, 2011 02:12 PM

The National Institutes of Health has finalized rules to reduce financial conflicts of interests among federally funded researchers who also receive payments or stock from drug and medical device companies, according to a report by the Washington Post.

More... »

FDA creates modernization plan

Tuesday, August 23, 2011 12:43 PM

The FDA is prioritizing development of technologies to compare biosimilars to innovator products in its plan to modernize regulatory science.

More... »

FDA approves first gene-targeted drug for Melanoma

Wednesday, August 17, 2011 12:05 PM

The FDA has approved Zelboraf, known as vemurafenib or PLX4032 during testing, well ahead of the approval deadline.  Zelboraf is the first drug to treat advanced melanoma by targeting a specific gene mutation.

More... »

FDA issues guidance to improve clinical study quality

Monday, August 15, 2011 01:40 PM

The FDA has issued draft guidance to help researchers and manufacturers design better quality clinical studies in support of premarket approval (PMA) applications for medical devices.

More... »

Regulatory requirements become more complex as clinical trials increase

Friday, August 12, 2011 10:45 AM

As pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory complexity is forcing them to change the way they operate, experts have warned, according to PharmaTimes.

More... »

BU professor fabricates data in two published experiments

Wednesday, August 10, 2011 11:43 AM

A cancer researcher and assistant professor at the Boston University School of Medicine Cancer Research Center fabricated data in two papers published in scientific journals, federal authorities announced, according to a report by the Boston Globe.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs